Analysis of Outcomes in COVID-19 Patients With Varying Degrees of Hyperlipasemia.

Autor:	Benias PC; From the Division of Gastroenterology, Lenox Hill Hospital, Zucker School of Medicine at Hofstra/Northwell, Northwell Health System, New York, NY., Inamdar S; Division of Gastroenterology, Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR., Wee D; Department of Medicine, Long Island Jewish Medical Center, Zucker School of Medicine at Hofstra/Northwell, Northwell Health System, New Hyde Park., Liu Y; Feinstein Institutes for Medical Research, Northwell Health, Manhasset., Buscaglia JM; Division of Gastroenterology & Hepatology, Renaissance School of Medicine at Stony Brook University, Stony Brook., Satapathy SK, Trindade AJ
Jazyk:	angličtina
Zdroj:	Pancreas [Pancreas] 2021 Oct 01; Vol. 50 (9), pp. 1310-1313.
DOI:	10.1097/MPA.0000000000001922
Abstrakt:	Objectives: Coronavirus disease 2019 (COVID-19) patients may have varying degrees of hyperlipasemia. The aim was to compare outcomes among different levels of hyperlipasemia in patients with COVID-19. Methods: This is a retrospective study examining outcomes among hospitalized COVID-19 patients with a lipase <3× upper limit of normal (ULN), asymptomatic hyperlipasemia (>3× ULN), secondary pancreatitis (typical respiratory COVID-19 symptoms and found to have pancreatitis), and primary pancreatitis (presenting with pancreatitis). Results: Of 11,883 patients admitted with COVID-19, 1560 patients were included: 1155 patients had normal serum lipase (control group), 270 had elevated lipase <3× ULN, 46 patients had asymptomatic hyperlipasemia with lipase >3× ULN, 57 patients had secondary pancreatitis, and 32 patients had primary pancreatitis. On adjusted multivariate analysis, the elevated lipase <3× ULN and asymptomatic hyperlipasemia groups had worse outcomes with higher mortality (odds ratio [OR], 1.6 [95% confidence interval [CI], 1.2-2.2) and 1.1 [95% CI, 0.5-2.3], respectively), higher need for mechanical ventilation (OR, 2.8 [95% CI, 1.2-2.1] and 2.8 [95% CI, 1.5-5.2], respectively), and longer length of stay (OR, 1.5 [95% CI, 1.1-2.0] and 3.16 [95% CI, 1.5-6.5], respectively). Conclusions: Patients with COVID-19 with elevated lipase <3× ULN and asymptomatic hyperlipasemia have generally worse outcomes than those with pancreatitis. Competing Interests: P.C.B. is a consultant for Olympus America, Apollo Medical, FujiFilm, and Boston Scientific. J.M.B. is a consultant and speaker for Abbvie Inc. A.J.T. is a consultant for Olympus America and Pentax Medical. The remaining authors declare no conflict of interest. (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu